{
    "2020-04-24": [
        [
            {
                "time": "",
                "original_text": "一季度基金大举进军港股 700亿 刘格菘还能继续辉煌？",
                "features": {
                    "keywords": [
                        "基金",
                        "港股",
                        "刘格菘",
                        "700亿"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "港股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "业绩增长伴随应收账款激增 康泰生物重营销轻研发吝分红",
                "features": {
                    "keywords": [
                        "业绩增长",
                        "应收账款",
                        "康泰生物",
                        "营销",
                        "研发",
                        "分红"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}